Disclosure: This is an affiliate site. We may earn compensation from partners. Full disclosure | Medical disclaimer
$50 a month for certain GLP-1 weight-loss medications, from July 1, 2026 through December 31, 2027.
Medicare has historically not covered medications used solely for weight loss. That changed on July 1, 2026, when CMS launched a temporary demonstration called the Medicare GLP-1 Bridge, giving eligible beneficiaries access to certain GLP-1 medications for $50 a month.
This is the single cheapest route to a brand-name GLP-1 currently available to anyone. At $50 a month it undercuts every cash-pay option on the market, including manufacturer-direct pricing at $149 and every compounded platform.
It is also temporary, limited to three specific products, and carries its own eligibility criteria that are stricter than standard FDA labelling. Here is exactly what it covers and who can use it.
The program runs from July 1, 2026 through December 31, 2027. Eligible Medicare beneficiaries pay $50 a month. Three products are covered: Foundayo tablets, Wegovy in both injection and tablet form, and the Zepbound KwikPen only — not Zepbound vials. Compounded GLP-1s are not eligible and never will be, because the program covers FDA-approved medication.
CMS specifies particular products and formulations. The Zepbound restriction to the KwikPen is easy to miss and matters if you are currently on vials.
| Medication | Formulation covered | Molecule | Manufacturer |
|---|---|---|---|
| Foundayo | Tablet | Orforglipron | Eli Lilly |
| Wegovy | Injection and tablet | Semaglutide | Novo Nordisk |
| Zepbound | KwikPen only | Tirzepatide | Eli Lilly |
Zepbound single-dose vials are not listed among the covered formulations. If you are on vials and want to use this program, that is a conversation to have with your prescriber.
Medicare.gov states that you must be 18 or older and meet one of its requirements when you start GLP-1 therapy, including a body mass index of 35 or higher. Reporting on the program also describes pathways for beneficiaries with a BMI between 30 and 35 who have associated conditions such as uncontrolled hypertension or advanced-stage chronic kidney disease.
These thresholds are notably stricter than the standard FDA label criteria of BMI 30, or BMI 27 with a weight-related condition. Qualifying clinically for a GLP-1 does not automatically mean qualifying for this program.
Because the exact criteria and any prior authorization requirements can be updated, Medicare.gov is the authoritative source. Check it before making decisions based on eligibility you have not confirmed.
Against the cheapest verified alternatives currently available.
| Route | Monthly cost | Annual cost | Medication |
|---|---|---|---|
| Medicare GLP-1 Bridge | $50 | $600 | Foundayo, Wegovy, Zepbound KwikPen |
| LillyDirect (Foundayo) | From $149 | From ~$1,788 | FDA-approved orforglipron |
| NovoCare (Wegovy tablets) | From $149 | From ~$1,788 | FDA-approved oral semaglutide |
| LillyDirect (Zepbound) | $299-$449 | ~$3,588-$5,388 | FDA-approved tirzepatide |
| Curex (compounded) | $149 all-in | ~$1,788 | Compounded, not FDA-approved |
| Commercial insurance savings | From $25 | From ~$300 | Where a plan covers the category |
The only route cheaper than the Bridge program is a commercial plan that covers weight-management medication with a low copay, or an employer-funded program such as Teladoc for eligible members.
Medicare has long been prohibited from covering drugs used solely for weight loss, a restriction dating from the original Part D design. As GLP-1s demonstrated cardiovascular and other health benefits beyond weight reduction, that exclusion became increasingly difficult to defend, but changing it permanently requires legislation.
The Bridge is a demonstration program — a time-limited CMS pilot that provides access while the longer-term policy question is resolved. That is why it has an end date of December 31, 2027 rather than being a permanent benefit.
Medicaid coverage has been expanding alongside this. If you are dual-eligible or on Medicaid, it is worth checking your state's current position separately, as coverage varies considerably by state.
July 1, 2026. It runs through December 31, 2027 as a temporary CMS demonstration program.
$50 a month for eligible beneficiaries under the GLP-1 Bridge program. That is the cheapest route to a brand-name GLP-1 currently available, undercutting manufacturer-direct self-pay pricing of $149 to $449 a month.
Three products: Foundayo tablets (orforglipron), Wegovy in both injection and tablet form (semaglutide), and the Zepbound KwikPen only (tirzepatide). Zepbound single-dose vials are not listed among the covered formulations.
Medicare.gov states you must be 18 or older and meet one of its requirements when starting GLP-1 therapy, including a BMI of 35 or higher. Reporting also describes pathways for a BMI between 30 and 35 with associated conditions such as uncontrolled hypertension or advanced chronic kidney disease. These criteria are stricter than standard FDA label eligibility — check Medicare.gov for the current requirements.
No. The program covers specific FDA-approved products, and compounded GLP-1s are not FDA-approved. There is no pathway for compounded medication under this or any insurance coverage.
The Bridge is a time-limited demonstration program with that end date. What replaces it, if anything, depends on future policy decisions. If you are relying on this coverage, plan for the transition rather than assuming it will be extended.
No. Only the Zepbound KwikPen formulation is listed among the covered products. If you currently use single-dose vials, discuss switching formulations with your prescriber before assuming your prescription qualifies.
It varies. Walgreens states its virtual weight management service does not currently support Medicare patients. Check with any telehealth provider before enrolling, and note that the Bridge program's $50 a month is cheaper than any telehealth cash-pay option regardless.
Commercial plans and prior authorization
One of the three covered products
For anyone not Medicare-eligible
Standard vs Medicare criteria
Every route priced out
Why compounded cannot be covered
Claims on this page trace to the following sources, checked on August 30, 2026.
Explore more expert guides and reviews to help you on your weight loss journey
Complete nutrition guide for GLP-1 users: what to eat, meal planning, and dietary strategies.
Evidence-based review of weight loss medications: what works, what doesn't, and expected results.
Understanding and preventing facial volume loss on GLP-1 medications with expert tips.
Complete guide to gallstone risk with GLP-1 medications: statistics, prevention strategies, and warning signs.
Understanding weight set point science and timeline for establishing permanent weight loss with GLP-1s.
Top 15 fruits for weight loss ranked by fiber, calories, and satiety—perfect for GLP-1 users.
This article summarizes publicly available information about a government program and is for informational purposes only. It is not medical, insurance, or legal advice. Program rules, covered products and eligibility criteria can change — Medicare.gov is the authoritative source. Confirm your own eligibility and coverage directly with Medicare or your plan before making treatment decisions. This page contains affiliate links, and we may earn compensation if you use them.
Date reviewed: August 30, 2026